Liver tissue in the ESSENCE trial
The tissue endpoints ask for improvement in one feature without worsening another. Even a single organ contains more than one verdict.
Biopsy-confirmed MASH
The ESSENCE phase 3 trial enrolled 1,197 people with biopsy-confirmed metabolic dysfunction-associated steatohepatitis, or MASH, with stage 2-3 fibrosis. The reported interim analysis covered 800 participants. Those are different counts within the same study, so the interim group deserves to remain explicit when the tissue results appear.
Fibrosis means scarring. The combination of a tissue-confirmed diagnosis and a specified fibrosis stage gives the liver findings their clinical setting. The paired endpoints intrigue me in their handling of inflammation and scarring together: improvement in one comes with a condition about the other.
A biopsy also brings the discussion to a tangible place. The endpoints concern changes in liver tissue, giving the argument a different texture from body-weight averages or the cardiovascular events described elsewhere on this site.
Steatohepatitis resolution and fibrosis
In the interim ESSENCE results, resolution of steatohepatitis without worsening fibrosis occurred in 62.9% of the semaglutide group and 34.3% of the placebo group. Fibrosis improvement without worsening steatohepatitis occurred in 36.8% and 22.4%, respectively.
Each endpoint pairs an improvement with a condition about the other tissue finding. The pairing makes abbreviation especially unsatisfying. Resolution of steatohepatitis and improvement in fibrosis ask different questions; both retain a safeguard about worsening of the other feature.
The larger percentages make resolution of steatohepatitis without worsening fibrosis the more immediately striking result to me. The fibrosis outcome is equally deserving of its full sentence. The endpoints specify steatohepatitis and fibrosis. A summary that let the phrase resolution spread beyond the endpoint actually measured would disappoint me.
The broader treatment picture
The semaglutide safety review describes predominantly mild-to-moderate, transient gastrointestinal effects and increased biliary-disease risk, alongside a favourable overall risk-benefit judgement in type 2 diabetes. Its population and purpose differ from this MASH trial. I wouldn’t borrow the reassuring judgement as a complete account of everyone enrolled in ESSENCE.
My next curiosity concerns the relationship between these tissue changes and later clinical outcomes for the people whose biopsies supplied the results. The interim findings give that question urgency. They leave open how improvement in tissue relates to the later course of disease.
The reading list places the tissue trial beside the cardiovascular, kidney and alcohol reports. Their shared medicine makes the company interesting; the overlapping outcomes complicate the division into organs.